Blockchain Registration Transaction Record

NeuroThera Labs Launches Phase IIb Trial for Tourette Syndrome Treatment in Germany

NeuroThera Labs initiates Phase IIb trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School in Germany. The study builds on promising Phase IIa results showing 21% tic reduction.

This news matters because Tourette Syndrome affects millions worldwide, yet treatment options remain limited, especially for adults with severe symptoms. A successful Phase IIb trial could lead to a novel cannabinoid-based therapy that reduces tics with fewer side effects, potentially improving quality of life for patients who have few alternatives. The involvement of top research institutions like Hannover Medical School, Yale, and Tel Aviv Sourasky Medical Center underscores the global need and scientific rigor behind this effort.